Kornimate/medical-research-clean huggingface dataset:
biomechanical analysis of gait in individuals with duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: the purpose of this research study is to understand the walking patterns, strength and function changes of boys with duchenne muscular dystrophy on/off corticosteroids to determine the best timing and treatment options to maintain walking for as long as possible.

duchenne muscular dystrophy (dmd) is an x-linked recessive disease of muscle characterized by a progressive loss of functional muscle mass, which is replaced with fibrofatty tissue. historically, boys with dmd lose the ability to walk between the ages of 8-12 years, due to progressive weakness of the quadriceps coupled with the development of contractures at the hip, knee and ankle. this progressive loss in function necessitates individuals with dmd to spend less time walking and more time in wheelchairs, leading to the development of spinal deformities. recently, corticosteroids have been shown to reduce the expected loss of muscle strength, extend the time that ambulation and standing are maintained, and minimize or eliminate spinal deformity in individuals with dmd; yet, the side effects of such treatment preclude use in some patients. to date, differences in gait patterns and other markers of disease progression between boys on corticosteroids and those not utilizing such treatment have not been objectively quantified. this lack of knowledge is a major obstacle to determining the most effective treatment for subsets of boys with dmd.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of dmd * male. * four years of age or older. * ability to walk independently for five minutes to 10 minutes at self-selected speed. * ability to cognitively understand directions for testing procedures. exclusion criteria: * female * nonambulatory

Keywords: walking muscle strength energy cost quality of life
safety and efficacy of two dosages of diractin® in osteoarthritis (oa)

Conditions: Osteoarthritis of the Knee

Summary: the purpose of this study is to provide replicated evidence of safety and efficacy of 50 mg and 100 mg ketoprofen in diractin®.

the study will investigate safety and efficacy of 2 dosages of diractin®at relieving the signs and symptoms of knee oa, including the primary endpoint of patient assessment of pain.

Eligibility criteria:
inclusion criteria: * informed consent signed and dated * age \> 45 years * class i-iii oa of the knee and subject meets american college of rheumatology (acr) clinical classification criteria for osteoarthritis of the knee exclusion criteria: * skin lesions or dermatological diseases in the treatment area * directly or indirectly involved in the conduct and administration of this study * received any investigational medicinal product within 30 days prior to screening visit or participation in any previous clinical study with diractin® * pregnancy or lactation * residents of psychiatric wards, prisons or other state institutions * malignancy within the past 2 years * depressive disorders requiring treatment with tricyclics, treatment with other antidepressants must be stable for 3 months prior to screening and throughout the study * epilepsy * schizophrenia * neuropathic pain and any other pain condition requiring chronic use of pain medication * known hypersensitivity or allergy (including photoallergy) to nsaid´s including ketoprofen, celecoxib, sulfonamides and ingredients used in pharmaceutical products including galactose * peripheral arterial disease and/or cerebrovascular disease * history of stroke or myocardial infarction * congestive heart failure nyha class ii-iv * history of pancreatitis or peptic ulcers; * inflammatory gi disease (e.g. m. crohn, colitis ulcerosa) * serum creatinine levels \> 2.5 milligrams/deciliter (mg/dl) * alt or ast levels ≥ 5 times the uln * unable to discontinue analgesic therapy including opioids, nsaid´s, tramadol, muscle relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs approved or used for the treatment of pain for the duration of the study
effect of oral enteral nutrition feeding in parkinson disease

Conditions: Parkinson Disease

Summary: the goal of this or clinical trial is to explore intermittent oro-esophageal tube feeding vs. nasogastric tube feeding on nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease, better than nasogastric tube feeding. participants will be divided into the control group and observation group evenly. all the patients were provided with routine therapy and given nutritional support by intermittent oro-esophageal tube feeding and nasogastric tube feeding respectively. the nutritional status, swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

nasogastric tube feeding has been widely used in patients with parkinson's disease but has a significant risk of complications. intermittent oro-esophageal tube feeding is an established enteral nutrition approach that can be used with comprehensive rehabilitation therapy. the goal of this or clinical trial is to explore intermittent oro-esophageal tube feeding vs. nasogastric tube feeding on nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease. the main question it aims to answer are: • can stellate ganglion block improve the nutritional status, dysphagia, and activities of daily living in patients with parkinson's disease, better than nasogastric tube feeding. participants will be divided into the control group and observation group evenly. all the patients were provided with routine therapy and given nutritional support by intermittent oro-esophageal tube feeding and nasogastric tube feeding respectively. the nutritional status, swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

Eligibility criteria:
inclusion criteria: * age \>18 years. * meeting the diagnostic criteria for parkinson's disease. * diagnosed with dysphagia confirmed by the video fluoroscopic swallowing study. * water swallow test\> level 3. * stable vital signs, conscious, able to cooperate with assessment and treatment. exclusion criteria: * dysphagia possibly caused by other reasons, such as cerebrovascular disease, trauma, neuromuscular diseases, malignant diseases of the pharynx and larynx, and digestive tract diseases. * complicated with cognitive impairment or consciousness dysfunction. * simultaneously suffering from severe liver, kidney failure, tumors, or hematological diseases. * complicated with severe liver and kidney failure, tumors, or hematological disorders.
angulated screw-retained crowns following immediate implant placement

Conditions: Tooth Diseases

Summary: there are two choices of restorations and implant abutments connection now: cemented and screw-retained.the excess cement, which would be difficult to completely remove, might lead to series of biological complications. the angulated screw channel (asc) abutments, which recently introduced by nobel biocare , largely address the problem with visible screw access that may compromise esthetics. however, all of the present studies were clinical reports, thus the clinical efficacy of asc abutments still needs the verification of evidence-based medicine with larger sample. therefore, we designed a randomized controlled clinical trial study, aiming to verify the clinical efficacy of the asc abutments by comparing screw-retained (with asc abutments) single implant crowns with cemented ones in esthetic region.


Eligibility criteria:
inclusion criteria: 1. ≥18 years old and in good health; 2. single tooth implant (type 1) in the esthetic region; 3. patients with natural teeth adjacent to single implant crowns; 4. patients with periodontal treatment before implant surgery; 5. the implants are from nobel biocare system with tapered link and the permanent restoration is a single crown and all-ceramic; 6. soft tissue in the implanting-and-adjacent areas is healthy and free of infection exclusion criteria: 1. multiple implants in the esthetic region, or the restoration is a bridge 2. patients with bone augmentation procedures; 3. heavy smokers (\>10 cigarettes/day); 4. medically compromised patients (american society of anesthesiologists (asa) classification iii-iv); 5. implants in an incorrect three-dimensional position (definition according to iti vol1); 6. uncontrolled diabetes mellitus; 7. unwilling to participate in the present study.
a study of ly03003 in patients with early-stage parkinson's disease

Conditions: Parkinson Disease

Summary: this study is to characterize the pharmacokinetics and to evaluate the safety as well as tolerability of ly03003 following multiple escalating intramuscular injections


Eligibility criteria:
inclusion criteria: * patient had parkinson's disease that meet the clinical diagnostic criteria of the brain bank of the parkinson's disease association of the united kingdom. * patient was hoehn \& yahr stage ≤3 (excluding stage 0) ; * patient was male or female aged 18 to 75 years; * patient had a mini mental state examination (mmse) score of ≥25; * patient had a unified parkinson's disease rating scale (updrs) motor score (part iii) of ≤30 at screening. * patient who signed the informed consent form volunteered to participate in this clinical trial and could cooperate with the prescribed inspections. exclusion criteria: * patient had a history of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant; * patient had dementia, schizophrenia or hallucinations, or clinically significant depression; * patient had a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or presence of suicidal tendency in the past year; * patient had a history of orthostatic hypotension. * patient had received therapy with a dopamine (da) agonist either concurrently or had done so within 28 days prior to the screening; * patient had received therapy with 1 of the following drugs either concurrently or within 28 days prior to screening: monoamine oxidase b (mao-b) inhibitors (e.g., pargyline, selegiline), da releasing agents (e.g., amphetamine), reserpine, da-antagonists (e.g., metoclopramide), neuroleptics, or other medications that may interact with da function; * patient was currently (at the time of screening) receiving central nervous system active therapy (e.g., sedatives, hypnotics, antidepressants, anxiolytics), unless the dose had been stable for at least 28 days prior to screening visit and was likely to remain stable for the duration of the study; * patient had a current diagnosis of epilepsy, had a history of seizures as an adult within 1 year prior to screening, had a history of stroke or transient ischemic attack within 3 months prior to screening; * patient had a history of known intolerance/hypersensitivity to non-dopaminergic antiemetics, such as domperidone, ondansetron, tropisetron; * patient had any other clinically relevant hepatic, renal, and cardiac dysfunction, or laboratory abnormality, which would have, in the judgment of the investigator, interfered with the patient's ability to participate in the study; * patient had a history of allergic to any medication; * heavy smoker, alcoholic, drug addict; * female patients who were pregnant or were breastfeeding or were of childbearing potential without adequate contraception; * patient who was inappropriate to participant in the study in the judgment of the investigator.

Keywords: parkinson disease ly03003
acceptability of depo-subq provera 104 in uniject vs. intramuscular depo-provera among hiv+ women & providers, uganda

Conditions: Acceptability of Different Contraceptive Injection Types

Summary: the purpose of this study is to assess acceptability and side effects of a low-dose injectable contraceptive formulation which is delivered under the skin (subcutaneously), as compared with injectable contraception delivered into the muscle (intramuscularly) among adult hiv-positive women who attend mobile clinics for hiv care and wish to use injectable contraception. the investigators will also assess experiences experiences delivering these two types of injections among health care providers working within the hiv care clinics.


Eligibility criteria:
inclusion criteria: * hiv+ * woman aged 18-45 * wishes to prevent pregnancy by use of injectable contraception and intends to continue using injectable contraception for next nine months * medically eligible for injectable contraception * capable of providing informed consent * willing to provide contact information * agrees to trial participation * intends to live in the area for the next nine months * may or may not be currently using a first-line antiretroviral therapy regimen (includes: azt/3tc/efv; azt/3tc/nvp; cbv/efv; d4t/3tc/efv; d4t/3tc/nvp; tdf/3tc/efv; tdf/3tc/nvp) exclusion criteria: * currently pregnant * desires pregnancy within next nine months * contraindications to using injectable contraception * on second-line antiretroviral therapy regimen

Keywords: injectable contraception acceptability intramuscular subcutaneous
clinical evaluation of fluid extract of chamomilla tincture for oral aphthae

Conditions: Recurrent Aphthous Stomatitis

Summary: recurrent aphthous stomatitis is a difficult to treat and quite common chronic inflammatory disease of the oral mucosa. this study evaluates the fluid extract from chamomilla recutita's safety and effectiveness in treatment of aphthous stomatitis .


Eligibility criteria:
inclusion criteria:• confirmation of clinical diagnosis of aphthae * having the experience of oral aphthae at least once in a month * two weeks wash out periods after the last treatment exclusion criteria: * history of any systemic disease * using drugs which affect immune system * pregnancy and breast feeding * aphthous related syndromes

Keywords: aphthous stomatitis; herbal medicines; matricaria chamomilla
a modified constraint-induced movement therapy program in rehabilitation of arm paresis in children with cerebral palsy

Conditions: Hemiparesis; Cerebral Palsy

Summary: the purpose of this study is to determine if a modified protocol of constraint-induced movement therapy (cit) is effective in rehabilitation treatment of arm paresis in children with cerebral palsy. in these children one main problem the non-use of the affected arm. many studies showed that the non-use phenomenon can by reversed by the cit, a rehabilitation program consisting of 15 days of restraining the unaffected arm plus a daily intensive (6 hours/day) physiotherapy training of the paretic arm. the present study aims at evaluating if a shortened cit protocol (restraining device plus only 2 weekly hours of physiotherapy) is effective in improving use and function of children paretic arm


Eligibility criteria:
inclusion criteria: * presence of mild-moderate arm paresis (after cerebral palsy) enabling to * reach and grasp a pellet * age between 1-10 years * active participation during proposed activities * parents consent for participation - exclusion criteria: * presence of severe behaviour disturbances * presence of severe mental retardation (qi\<60)

Keywords: rehabilitation children cerebral palsy arm paresis
comparison of exercise therapies for patellofemoral pain

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain (pfp) is a common knee problem, primarily affecting adolescents and young adults. pfp is characterised by significant retropatellar and/or peripatellar pain and impairment of function and quality of daily life. exercise therapy is unequivocally recommended as a core component of the management of pfp. different exercise types (e.g. quadriceps strengthening, hip strengthening and functional/neuromuscular exercises) have been investigated, with knee and hip strengthening exercises as the most common and recommended types. these exercises approaches produce similar small to moderate effects on pain and physical function. however, the pfp population is very heterogeneous and "one-size-fits-all"-approaches presumably are sub-optimal because the heterogeneity is ignored. the heterogeneity probably explains the overall limited beneficial effects of exercise, and the lack of differences in direct comparisons of different exercise types. in that sense, it is not unlikely that certain patient characteristics may predict outcome success of either a hip training program or a training program that focus on the quadriceps but this remains to be shown. this study has two aims: 1. to assess the comparative effectiveness of two different exercise programs (quadricep exercise \[qe\] vs. hip exercise \[he\]) on self-reported pain and function in individuals with pfp. 2. to explore candidate patient characteristics that predict differential responses to the two exercise programs (qe vs he) on self-reported pain and physical function in individuals with pfp. according to the study aims we pursue the following hypothesis: - qe and he have equivalent efficacy on self-reported pain after 12 weeks of treatment in patients with pfp. the second study aim is to explore possible candidate patient characteristics that may associate with differential outcomes. as this is exploratory, the pursuit of this aim is hypothesis-free.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of pfp in at least one knee * visual analogue score rating of pain during activities of daily living during the previous week at a minimum of 3 on a 10 cm scale. * insidious onset of symptoms unrelated to trauma and persistent for at least 4 weeks. * pain in the anterior knee associated with at least 3 of the following: * during or after activity * prolonged sitting * stair ascent or descent * squatting exclusion criteria: * meniscal or other intra-articular injury * cruciate or collateral ligament laxity or tenderness * patellar tendon, iliotibial band, or pes anserine tenderness * osgood-schlatter or sinding-larsen-johansson syndrome * history of recurrent patellar subluxation or dislocation * history of surgery to the knee joint * history of head injury or vestibular disorder within the last 6 months
hydroxychloroquine in mild graves' orbitopathy

Conditions: Graves Ophthalmopathy

Summary: this study is aimed to investigate the effect of hydroxychloroquine in patients with mild graves' orbitopathy (go).

graves' orbitopathy (go) is one of the common manifestations of graves' disease (gd), which results in proptosis, eyelid retraction, soft tissue swelling, diplopia or even visual acuity impairment. in addition, mental health and quality of life are often affected. in current guidelines, limited treatment options are suggested for patients with mild go. recently, cell study revealed that there are multiple effects of hydroxychloroquine (hcq) on orbital fibroblasts in patients with mild go, including suppression of cell proliferation, adipogenesis and production of hyaluronic acid, which poses a great potential in the treatment of mild go clinically. this randomized controlled trial is aimed to investigate the effects of hcq in patients with mild go on the effects of ophthalmic outcomes, quality of life, orbital volumetry on orbital computed tomography, serum inflammatory and fibrosis markers.

Eligibility criteria:
inclusion criteria: * mild go according european group on graves' orbitopathy (eugogo) guidelines diagnosed by endocrinologist and ophthalmologist. * no previous treatment of go except for eyedrops * euthyroidism (normalized free t4 and tsh) for at least 2 months. if radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months. exclusion criteria: * moderate-to-sever or sight-threatening go according to eugogo guidelines diagnosed by endocrinologist and ophthalmologist. * pregnancy * drug or alcohol abuse * unable to comply with the study protocol * unable to obtain informed consent * use of hydroxychloroquine or systemic steroid within 3 months prior to enrollment * history of side effects of hydroxychloroquine * history of retinopathy * renal dysfunction (estimated glomerular filtration rate (egfr) \< 60ml/min) * hepatic dysfunction (aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 2 x upper limit) * anemia (hemoglobin (hb) \< 10g/dl) * neutropenia (absolute neutrophil count \< 100/ul) * thrombocytopenia (platelet (plt) \< 150000/ul) * glucose-6-phosphate dehydrogenase (g6pd) deficiency * porphyria cutaneous tarda * allergy to 4-aminoquinoline

Keywords: graves' ophthalmopathy graves' disease hydroxychloroquine orbital volumetry go-qol questionnaire
art-3 pilot - driving pressure limited ventilation for patients without ards (art3pilot)

Conditions: Mechanical Ventilation; Acute Respiratory Distress Syndrome

Summary: this is a multicenter randomized controlled pilot trial to investigate the feasibility of a driving pressure limited mechanical ventilation strategy compared to a conventional strategy in patients without acute respiratory distress syndrome (ards).

mechanical ventilation has the potential to produce or worsen alveolar injury. driving pressure is the difference between plateau pressure and peep. evidence from observational studies suggests that elevated driving pressure is the main independent determinant of ventilator-induced lung injury, however clinical trials are needed to establish whether targeting low driving pressures can improve clinical outcomes in patients without acute respiratory distress syndrome (ards). thus, art-3 pilot is a multicenter randomized controlled trial to assess the feasibility of a driving pressure limited mechanical ventilation strategy compared to a conventional strategy in patients without ards. patients considered to this trial are those in mechanical ventilation for less than 72 hours without diagnosis of ards. we will exclude patients with less than 18 years old; contraindication to hypercapnia such as intracranial hypertension or recent acute coronary syndrome; patients in which a high probability of death within 24 hours is anticipated and patients under exclusive palliative care. eligible patients will be randomized to the driving pressure limited ventilation strategy or conventional strategy (tidal volume of 8 ml/kg of predicted body weight). the primary outcome is driving pressure between days 1 and 3.

Eligibility criteria:
inclusion criteria: * patients on invasive mechanical ventilation for less than 72 hours and without diagnosis of ards, and no perspective of extubation in 24 hours. exclusion criteria: * less than 18 years old * presence of any contraindication to hypercapnia as suspected or confirmed intracranial hypertension or recent (\<7 days) acute coronary syndrome. * patients in which a high probability of death within 24 hours is anticipated. * patients under exclusive palliative care.

Keywords: patients ards diagnosis